SHANGHAI

上海

,

，

June 5, 2025

2025年6月5日

/PRNewswire/ -- Qure Biotechnology (

/PRNewswire/ -- Qure生物技术公司 (

Shanghai

上海

) Co., Ltd. (QureBio) announced that it has completed a Series C1 financing round. The financing raised nearly

) 有限公司 (QureBio) 宣布已完成 C1 轮融资。此轮融资筹集了近

CNY 100 million

人民币一亿元

(approximately

（大约

USD 14 million

1400万美元

) and was led exclusively by Efung Capital. This infusion of capital will be used to accelerate QureBio's clinical trials and advance its pipeline of novel antibody therapeutics.

）并由Efung Capital独家领投。这笔资金将用于加速QureBio的临床试验，并推进其新型抗体治疗药物的研发管线。

Therapeutic Focus and Technology Platforms

治疗重点与技术平台

QureBio specializes in developing bispecific and multispecific antibody and protein therapeutics to address unmet medical needs in cancer, autoimmune diseases, and inflammatory disorders. The company has established a suite of proprietary technology platforms – including its I2T platform and its T-cell engager and NK-cell engager platforms – which form the foundation for its pipeline of novel drug candidates.

QureBio专注于开发双特异性和多特异性抗体及蛋白质疗法，以满足癌症、自身免疫疾病和炎症性疾病中未被满足的医疗需求。公司建立了多个专有技术平台，包括其I2T平台、T细胞衔接器和NK细胞衔接器平台，这些平台构成了其新型候选药物管线的基础。

Using these platforms, QureBio has built a robust pipeline of therapeutics aimed at previously intractable diseases..

利用这些平台，QureBio 已建立了一条强大的治疗药物管道，针对以前难以治愈的疾病。

Pipeline Highlights

管道亮点

Key pipeline developments include:

关键的管道发展包括：

Q-1802 (Claudin18.2/PD-L1 bispecific antibody):

Q-1802（Claudin18.2/PD-L1双特异性抗体）：

Received regulatory clearance to initiate clinical trials in both

已获得在两地启动临床试验的监管批准

China

中国

and

和

the United States

美国

in

在

March 2021

2021年3月

. Phase II patient enrollment is nearly complete, and preparations are underway for Phase III clinical trials in

第二阶段的患者招募已接近完成，并且正在为第三阶段的临床试验做准备。

China

中国

.

。

Q-1801 (SIRPα/PD-L1 bispecific antibody):

Q-1801（SIRPα/PD-L1双特异性抗体）：

Obtained clinical trial approvals in

获得临床试验批准在

China

中国

and the US, and is poised to begin clinical studies.

并且在美国也准备开始临床研究。

PD-1 Antibody-Cytokine Fusion Candidate:

PD-1抗体-细胞因子融合候选物：

An innovative fusion protein with dual functions as a PD-1 checkpoint inhibitor and a cytokine modulator, demonstrating a favorable therapeutic window. This candidate targets an area where similar approaches by larger biopharmaceutical companies have faced setbacks, and QureBio is seeking partners to accelerate its global development..

一种具有双重功能的创新融合蛋白，作为PD-1检查点抑制剂和细胞因子调节剂，展现出良好的治疗窗口。该候选药物针对的是较大生物制药公司在类似方法上遭遇挫折的领域，QureBio正在寻求合作伙伴以加速其全球开发。

Strategic Partnerships and Industry Recognition

战略合作伙伴关系与行业认可

QureBio's proprietary antibody engineering technology has garnered broad industry recognition. Leveraging its platform capabilities, the company has established collaborations with leading biotechnology and pharmaceutical firms – including BRL Medicine, BioMap, Hengrui Pharma, and Precision Scientific – to co-develop novel therapies.

QureBio专有的抗体工程技术获得了广泛的行业认可。利用其平台能力，该公司已经与领先的生物技术和制药公司建立了合作关系，包括百济神州、博雅辑因、恒瑞医药和精锋医疗，共同开发新型疗法。

These partnerships underscore QureBio's status as an emerging leader in innovative biopharmaceuticals..

这些合作伙伴关系凸显了QureBio作为创新生物制药领域新兴领导者的地位。

About QureBio

关于QureBio

Qure Biotechnology (

奎尔生物技术（

Shanghai

上海

) Co., Ltd. (QureBio) is a biopharmaceutical company founded in 2017 and based in

）有限公司（QureBio）是一家成立于2017年，总部位于

Shanghai, China

中国上海

. The company specializes in the research and development of innovative antibody and protein therapeutics, focusing on bispecific and multispecific antibodies for oncology, autoimmune diseases, and inflammatory disorders. QureBio has built multiple proprietary technology platforms for antibody discovery and engineering, enabling a robust pipeline of drug candidates aimed at addressing critical unmet medical needs in .

公司专注于创新抗体和蛋白质治疗药物的研发，重点是针对肿瘤学、自身免疫疾病和炎症性疾病的双特异性和多特异性抗体。QureBio 已建立了多个专有的抗体发现和工程化技术平台，形成了一个强大的候选药物管线，旨在满足关键的未满足医疗需求。

China

中国

and around the world.

世界各地。

Qu

曲

,

，

Xiangdong,

向东，

the

the

founder of Qure Bio, said:

Qure Bio创始人表示：

We express our appreciation to Efung Capital, a leading Chinese VC/PE focusing on Biomedicine, for its trust and support in QureBio.  As an innovation-driven biotech company focused on pioneering biopharmaceuticals, we will continue leveraging our proprietary bispecific and multispecific antibody technology platforms to develop novel therapies for unmet clinical needs include malignancies, autoimmune diseases, and inflammation-based disorders.

我们对国内领先、专注于生物医药领域的创投机构翼朴资本对QureBio的信任和支持表示感谢。作为一家创新驱动型的生物科技公司，我们将继续利用自主开发的双特异性抗体和多特异性抗体技术平台，针对包括恶性肿瘤、自身免疫性疾病以及炎症类疾病在内的未满足临床需求，开发新型治疗药物。

We look forward to collaborating with partners to develop novel therapies to benefit patients worldwide. .

我们期待与合作伙伴携手开发创新疗法，造福全球患者。

Fan

风扇

,

，

Rongkui, lead investor in this round of financing from

荣魁，本轮投资的领投方

Efung

益丰

Capital, said:

资本，说道：

There are numerous companies engaged in the development of Claudin18.2 targets, and different products have demonstrated promising therapeutic potential across various treatment lines. As a promising model, the Claudin18.2 bispecific antibody holds the potential to achieve unique clinical value in first-line therapy for gastric cancer.

有许多公司参与到Claudin18.2靶点的开发中，不同产品在各治疗线中展现了良好的治疗潜力。而Claudin18.2双特异性抗体作为一种有前景的模式，有可能在胃癌的一线治疗中实现独特的临床价值。

Efung Capital is optimistic about the advancement of Q-1802 into Phase III clinical trials, aiming to provide gastric cancer patients with innovative products that offer differentiated efficacy and align with national circumstances. Additionally, the company's founding team has a deep understanding of tumor immunology mechanisms, with core members having previously led R&D efforts at multinational pharmaceutical companies such as Amgen, Eli Lilly, and Pfizer, combining international perspectives with the ability to localize industrialization.

Efung资本看好Q-1802进入三期临床试验，旨在为胃癌患者提供具有差异化疗效且符合国情的创新产品。此外，公司创始团队对肿瘤免疫学机制有深刻理解，核心成员曾在安进、礼来、辉瑞等跨国药企主导过研发工作，兼具国际视野与本土产业化能力。

The core team has demonstrated exceptional efficiency in key areas such as target validation, molecular design, and process development, and has subsequently developed an early-stage differentiated R&D pipeline covering solid tumors and autoimmune diseases..

核心团队在靶点验证、分子设计和工艺开发等关键领域展示了卓越的效率，并随后开发了覆盖实体瘤和自身免疫疾病的早期差异化研发管线。

About

关于

Efung Capital

盈富资本

Efung Capital is one of the earliest professional biopharmaceutical investment institutions in

Efung Capital 是最早的专业生物医药投资机构之一

China

中国

. Its investment team consists of a group of PhDs in biopharmaceuticals from top universities in

其投资团队由一群来自顶尖大学的生物制药博士组成，

China

中国

and abroad, focusing on global biopharmaceutical VC/PE investments. It has conducted in-depth screening and invested in companies such as CHIPSCREEN, FRONTIER BIOTECHNOLOGIES Inc., Ascentage Pharma, Lifotronic, HARBOUR BIOMED, Obio Technology, ASIERIS, 3D-Medicines, Genuine Biotech, Apexigen, Centrexion, and Elicio, among other high-quality domestic and international companies.

并在全球范围内专注于生物制药领域的风险投资/私募股权投资。它已进行了深入筛选，并投资了诸如CHIPSCREEN、前沿生物技术公司、亚盛医药、理邦仪器、和铂医药、奥比奥技术、爱科瑞思、3D-医药、真诺生物、Apexigen、Centrexion和Elicio等高质量的国内外公司。

With its outstanding investment performance and exceptional research and investment capabilities, Efung Capital has been honored with numerous industry accolades, including multiple awards such as the Qianke Top 30 Investment Institutions in .

凭借其卓越的投资业绩和出色的研究投资能力，易方达资本荣获了众多行业奖项，其中包括多次获得清科Top30投资机构等奖项。

China's

中国的

Healthcare Sector, China Venture Capital Top 100, China Venture Capital Top 10 Best Exit Cases of the Year, China Venture Capital Top 10 Best Biomedical Investment Institutions of the Year, China Venture Capital Top 30 Best Venture Capital Institutions in the

医疗健康领域，中国风险投资百强，中国风险投资年度十佳退出案例，中国风险投资年度十佳生物医药投资机构，中国风险投资年度前三十最佳风险投资机构

Guangdong

广东

-Hong Kong-Macao Greater Bay Area of the Year, China Venture Capital Top 100 Chinese Venture Capital Institutions of the Year, Fund of Funds Top 30 Best Healthcare Investment Institutions of the Year, and

粤港澳大湾区年度投资机构、中国创业投资百强机构、母基金三十强最佳医疗健康领域投资机构，

China's

中国的

Most Dynamic Drug Innovation Investment Institutions. It has been consecutively named one of the 'Top 10 Venture Capital Institutions in

最具活力的药物创新投资机构。它连续被评为“十大风险投资机构之一

Shenzhen

深圳

' for multiple years and has been featured in an exclusive interview by the world-renowned journal Nature. Efung Capital aims to drive the industrialization of biotechnology achievements through capital investment.

多年并被世界知名期刊《自然》独家专访报道。易方资本旨在通过资本投入推动生物技术成果的产业化。

SOURCE QureBio Ltd.

源奎生物有限公司

WANT YOUR COMPANY'S NEWS

想要贵公司的新闻吗

FEATURED ON PRNEWSWIRE.COM?

刊登在PRNEWSWIRE.COM上？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers

影响者

9k+

9k+

Digital Media

数字媒体

Outlets

插座

270k+

27万+

Journalists

记者

Opted In

已选择加入

GET STARTED

开始使用